Ovid Therapeutics Inc.
OVID- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636651
No open-market purchases or sales by Ovid Therapeutics Inc. insiders were filed in the last 90 days; 130 institutions reported holding it in 13F filings for Q2 2026, worth $395.5M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Ovid Therapeutics Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 60 | 61 | +1 |
| Shares | 38.6M | 38.7M | +106.7K (+0.3%) |
| Value | $71.7M | $99.8M | +$28.1M (+39.1%) |
New holders (8)
Institutions that held Ovid Therapeutics Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Y-Intercept (Hong Kong) Ltd | 35,116 | $90.6K | 0.01% |
| Man Group plc | – | $71.6K | 0.00% |
| Balyasny Asset Management LLC | 24,056 | $62.1K | 0.00% |
| Virtu Financial LLC | 17,892 | $46.0K | 0.00% |
| Squarepoint Ops LLC | 11,271 | $29.1K | 0.00% |
| Point72 Middle East FZE | 5,993 | $15.5K | 0.00% |
| Cubist Systematic Strategies, LLC | 5,155 | $13.3K | 0.00% |
| Simplex Trading, LLC | 422 | $1.00K | 0.00% |
Sold out (7)
Institutions that held Ovid Therapeutics Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Oasis Management Co Ltd. | 270,000 | $502.2K |
| Ergoteles LLC | 75,923 | $141.2K |
| SEI Investments Co | 33,832 | $62.9K |
| Two Sigma Advisers, LP | 14,000 | $26.0K |
| ExodusPoint Capital Management, LP | 13,392 | $25.0K |
| Tri Locum Partners LP | 10,009 | $19.0K |
| Citigroup Inc | 1,237 | $2.30K |